ST Pharm Co Ltd
KOSDAQ:237690
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Yum! Brands Inc
NYSE:YUM
|
US |
|
R
|
Ratos AB
STO:RATO B
|
SE |
|
Zealand Pharma A/S
CSE:ZEAL
|
DK |
ST Pharm Co Ltd
Total Current Liabilities
ST Pharm Co Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Total Current Liabilities
₩147.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Total Current Liabilities
₩3.8T
|
CAGR 3-Years
-3%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Total Current Liabilities
₩10.5B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Total Current Liabilities
₩7.3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
10%
|
|
|
F
|
FutureChem Co Ltd
KOSDAQ:220100
|
Total Current Liabilities
₩14.9B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Total Current Liabilities
₩66.4B
|
CAGR 3-Years
70%
|
CAGR 5-Years
50%
|
CAGR 10-Years
59%
|
|
ST Pharm Co Ltd
Glance View
Nestled in the bustling metropolis of Seoul, South Korea, ST Pharm Co Ltd. operates as a dynamic player within the global pharmaceutical industry. Established initially to meet the burgeoning demands of the local pharmaceutical market, the company has slowly carved out a niche for itself in the global arena. With a deft focus on the development and manufacture of active pharmaceutical ingredients (APIs), ST Pharm now sets its sights on becoming a central figure in the synthesis of high-value APIs used in therapies including antivirals and oncology treatments. This focus isn't merely driven by opportunity; it's underpinned by a dedicated commitment to cutting-edge research and development. The company has invested heavily in state-of-the-art facilities and nurtures a team of seasoned scientists who remain at the forefront of innovation. ST Pharm makes its revenue by mastering the art of efficient and reliable API production. By optimizing their production processes, they can offer a competitive edge—delivering high-quality products at scale. The company isn't solely interested in the immediate gains of API manufacture; it also sees potential in providing customized solutions to its diverse clientele, which spans multinational pharmaceutical giants to nimble biotech startups. Partnerships and collaborations have become crucial strategies for ST Pharm, facilitating an exchange of innovation and expertise that keeps them relevant and forward-thinking. In this regard, their business model elegantly balances between standardized API production and bespoke chemical solutions, ensuring a steady revenue stream while opening doors to future advancements in pharmaceutical science.
See Also
What is ST Pharm Co Ltd's Total Current Liabilities?
Total Current Liabilities
147.6B
KRW
Based on the financial report for Sep 30, 2025, ST Pharm Co Ltd's Total Current Liabilities amounts to 147.6B KRW.
What is ST Pharm Co Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
49%
Over the last year, the Total Current Liabilities growth was 82%. The average annual Total Current Liabilities growth rates for ST Pharm Co Ltd have been 20% over the past three years , 49% over the past five years .